Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) - Net Assets
Based on the latest financial reports, Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) has net assets worth CN¥11.99 Billion CNY (≈ $1.75 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.76 Billion ≈ $2.01 Billion USD) and total liabilities (CN¥1.77 Billion ≈ $259.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603392 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥11.99 Billion |
| % of Total Assets | 87.12% |
| Annual Growth Rate | 33.31% |
| 5-Year Change | 163.74% |
| 10-Year Change | 1153.83% |
| Growth Volatility | 48.93 |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Beijing Wantai Biological Pharmacy Enterprise Co Ltd's net assets have evolved over time, based on quarterly financial data. See 603392 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Beijing Wantai Biological Pharmacy Enterprise Co Ltd (2013–2025)
The table below shows the annual net assets of Beijing Wantai Biological Pharmacy Enterprise Co Ltd from 2013 to 2025. For live valuation and market cap data, see market value of Beijing Wantai Biological Pharmacy Enter.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥12.03 Billion ≈ $1.76 Billion |
-3.33% |
| 2024-12-31 | CN¥12.45 Billion ≈ $1.82 Billion |
-3.38% |
| 2023-12-31 | CN¥12.88 Billion ≈ $1.89 Billion |
+2.54% |
| 2022-12-31 | CN¥12.56 Billion ≈ $1.84 Billion |
+175.40% |
| 2021-12-31 | CN¥4.56 Billion ≈ $667.64 Million |
+76.81% |
| 2020-12-31 | CN¥2.58 Billion ≈ $377.59 Million |
+63.24% |
| 2019-12-31 | CN¥1.58 Billion ≈ $231.31 Million |
+15.35% |
| 2018-12-31 | CN¥1.37 Billion ≈ $200.54 Million |
+52.44% |
| 2017-12-31 | CN¥898.99 Million ≈ $131.55 Million |
-6.33% |
| 2016-12-31 | CN¥959.70 Million ≈ $140.43 Million |
+32.80% |
| 2015-12-31 | CN¥722.69 Million ≈ $105.75 Million |
+24.53% |
| 2014-12-31 | CN¥580.32 Million ≈ $84.92 Million |
+51.89% |
| 2013-12-31 | CN¥382.06 Million ≈ $55.91 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Wantai Biological Pharmacy Enterprise Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3001.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥6.83 Billion | 57.60% |
| Other Components | CN¥5.03 Billion | 42.40% |
| Total Equity | CN¥11.86 Billion | 100.00% |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Competitors by Market Cap
The table below lists competitors of Beijing Wantai Biological Pharmacy Enterprise Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UNIQA Insurance Group AG
VI:UQA
|
$5.08 Billion |
|
AURA MINERALS INC. O.N.
F:A531
|
$5.08 Billion |
|
Wuxi Taclink Optoelectronics Technology Co. Ltd. A
SHG:688205
|
$5.09 Billion |
|
Caris Life Sciences, Inc. Common Stock
NASDAQ:CAI
|
$5.09 Billion |
|
Budimex S.A.
WAR:BDX
|
$5.08 Billion |
|
Selective Insurance Group, Inc.
NASDAQ:SIGI
|
$5.08 Billion |
|
Chenbro Micom Co Ltd
TW:8210
|
$5.07 Billion |
|
CONVATEC GRP UNSP.ADR /4
F:2CVU
|
$5.07 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Wantai Biological Pharmacy Enterprise Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,262,802,018 to 11,864,608,262, a change of -398,193,756 (-3.2%).
- Net loss of 398,267,667 reduced equity.
- Dividend payments of 2,277,527 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-398.27 Million | -3.36% |
| Dividends Paid | CN¥2.28 Million | -0.02% |
| Other Changes | CN¥2.35 Million | +0.02% |
| Total Change | CN¥- | -3.25% |
Book Value vs Market Value Analysis
This analysis compares Beijing Wantai Biological Pharmacy Enterprise Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.93x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 70.89x to 2.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.39 | CN¥27.45 | x |
| 2014-12-31 | CN¥0.57 | CN¥27.45 | x |
| 2015-12-31 | CN¥0.67 | CN¥27.45 | x |
| 2016-12-31 | CN¥0.87 | CN¥27.45 | x |
| 2017-12-31 | CN¥0.86 | CN¥27.45 | x |
| 2018-12-31 | CN¥1.26 | CN¥27.45 | x |
| 2019-12-31 | CN¥1.42 | CN¥27.45 | x |
| 2020-12-31 | CN¥2.14 | CN¥27.45 | x |
| 2021-12-31 | CN¥3.63 | CN¥27.45 | x |
| 2022-12-31 | CN¥9.88 | CN¥27.45 | x |
| 2023-12-31 | CN¥10.08 | CN¥27.45 | x |
| 2024-12-31 | CN¥9.23 | CN¥27.45 | x |
| 2025-12-31 | CN¥9.38 | CN¥27.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Wantai Biological Pharmacy Enterprise Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -21.90%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.18x
- Recent ROE (-3.36%) is below the historical average (18.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 20.89% | 16.00% | 0.82x | 1.59x | CN¥41.62 Million |
| 2014 | 20.41% | 19.87% | 0.74x | 1.39x | CN¥60.43 Million |
| 2015 | 17.30% | 17.53% | 0.62x | 1.60x | CN¥50.37 Million |
| 2016 | 16.67% | 17.56% | 0.58x | 1.64x | CN¥59.28 Million |
| 2017 | 17.12% | 15.84% | 0.57x | 1.89x | CN¥62.57 Million |
| 2018 | 21.71% | 29.82% | 0.54x | 1.34x | CN¥158.07 Million |
| 2019 | 13.40% | 17.64% | 0.55x | 1.39x | CN¥52.98 Million |
| 2020 | 26.51% | 28.76% | 0.67x | 1.37x | CN¥421.63 Million |
| 2021 | 45.26% | 35.15% | 0.82x | 1.58x | CN¥1.57 Billion |
| 2022 | 38.37% | 42.34% | 0.69x | 1.32x | CN¥3.50 Billion |
| 2023 | 9.82% | 22.64% | 0.35x | 1.24x | CN¥-22.38 Million |
| 2024 | 0.87% | 4.73% | 0.15x | 1.20x | CN¥-1.12 Billion |
| 2025 | -3.36% | -21.90% | 0.13x | 1.18x | CN¥-1.58 Billion |
Industry Comparison
This section compares Beijing Wantai Biological Pharmacy Enterprise Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,149,922,135
- Average return on equity (ROE) among peers: -7.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) | CN¥11.99 Billion | 20.89% | 0.15x | $5.08 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $352.52 Million | -169.05% | 0.63x | $5.04 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $7.92 Billion | 9.41% | 0.17x | $1.30 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $114.46 Million | 16.43% | 1.34x | $363.16 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $721.59 Million | 0.83% | 0.13x | $494.15 Million |
| Chengzhi Shareholding Co Ltd (000990) | $783.92 Million | 7.05% | 0.80x | $1.51 Billion |
| Hualan Biological EngineeringInc (002007) | $4.44 Billion | 17.59% | 0.05x | $3.38 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $1.04 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $11.73 Billion | 13.75% | 0.13x | $4.33 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.00 Billion | 6.64% | 0.50x | $490.62 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.35 Billion | 14.07% | 0.06x | $1.61 Billion |
About Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. The company offers in vitro diagnostics and automated laboratory instruments, including Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers; chemiluminescence and biochemistry tests, including novel diagnostic tests fo… Read more